MedMira Receives Health Canada Approval for Fast Syphilis Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: Yahoo Finance
- Rapid Testing Milestone: MedMira received Health Canada approval for its Reveal®TP (Syphilis) rapid test in Q1 FY2026, making it the fastest syphilis antibody test approved in Canada, aimed at combating rising infectious disease rates.
- Clinical Trial Progress: The company has commenced the second phase of clinical trials for its Multiplo®Complete Syphilis Antibody Test, aiming to provide additional patient data for regulatory submission, with completion anticipated in Q1 2026.
- Financial Performance: In Q1 FY2026, the company reported revenues of $54,208, down from $61,723 in the same period last year, but net loss improved from $1,300,549 to $813,134, indicating a positive trend in loss reduction.
- Asset and Liability Changes: The company experienced a decrease in assets by $86,053 and an increase in liabilities by $727,081, leading to a higher working capital deficit of $2,502,278, reflecting financial pressure and the need for restructuring.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIR
Wall Street analysts forecast MIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIR is 30.67 USD with a low forecast of 29.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.290
Low
29.00
Averages
30.67
High
34.00
Current: 25.290
Low
29.00
Averages
30.67
High
34.00
About MIR
Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
- vTv Therapeutics Rating: Roth Capital analyst Adam Walsh initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $58, indicating significant upside potential from its current price of $33.54.
- MasTec Upgrade: Cantor Fitzgerald analyst Manish Somaiya initiated coverage on MasTec Inc (NYSE:MTZ) with an Overweight rating and a price target of $274, suggesting strong market optimism given its current price of $244.57.
- e.l.f. Beauty Analysis: Citigroup analyst Filippo Falorni initiated coverage on e.l.f. Beauty Inc (NYSE:ELF) with a Buy rating and a price target of $110, reflecting confidence in the brand's growth potential from its current price of $95.34.
- Decoy Therapeutics Outlook: Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on Decoy Therapeutics Inc (NASDAQ:DCOY) with a Buy rating and a price target of $2.5, indicating positive expectations for its market performance from its current price of $0.7505.
Continue Reading
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
- Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
- Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
- Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
- Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.
Continue Reading